Reported Friday, BridgeBio's Attruby Earns FDA Nod As First Therapy With ≥90% TTR Stabilization, Offering Hope For ATTR-CM Patients

Benzinga · Nov 25 15:31

Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR as a transport protein of thyroxine and vitamin A and to demonstrate benefit on cardiovascular outcomes
Attruby demonstrated the most rapid benefit seen in any Phase 3 study of ATTR-CM to date:
In as few as 3 months, the time to first event (all-cause mortality (ACM) or cardiovascular-related hospitalizations (CVH)) durably separated relative to placebo
A 42% reduction in composite ACM and recurrent CVH events relative to placebo at Month 30
A 50% reduction in the cumulative frequency of CVH events relative to placebo at Month 30
To honor the courage of our U.S. clinical trial participants, BridgeBio will provide these patients Attruby free for life
To learn about our extensive suite of programs to provide access to Attruby call 1-888-55-BRIDGE (1-888-552-7434)
With this approval, BridgeBio will receive a $500 million payment under our royalty funding agreement

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more

Reported Friday, BridgeBio's Attruby Earns FDA Nod As First Therapy With ≥90% TTR Stabilization, Offering Hope For ATTR-CM Patients

Risk Disclaimer